Shona Kirtley

Shona Kirtley

Auto-generated profile, based on publicly available information

Shona Kirtley

Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, UK

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2021 in Systematic Reviews
Verified
Journal Article
Open access
PDF file
MRMelissa Rethlefsen
Melissa Rethlefsen
SKShona Kirtley
Shona Kirtley
SWSiw Waffenschmidt
Siw Waffenschmidt
AAAna Patricia Ayala
Ana Patricia Ayala
DMDavid Moher
David Moher
JKJonathan B. Koffel
Jonathan B. Koffel
Background: Literature searches underlie the foundations of systematic reviews and related review types. Yet, the literature searching component of systematic reviews and related review types is often poorly reported. Guidance for literature search reporting has been diverse, and, in many cases, does not offer enough detail to authors who need more specific information about reporting search methods and information sources in a clear, reproducible way. This document presents the PRISMA-S (Preferred Reporting Items for Systematic reviews and Meta-Analyses literature search extension) checklist, and explanation and elaboration. Methods: The checklist was developed using a 3-stage Delphi survey process, followed by a consensus conference and public review process. Results: The final checklist includes 16 reporting items, each of which is detailed with exemplar reporting and rationale. Conclusions: The intent of PRISMA-S is to complement the PRISMA Statement and its extensions by providing a checklist that could be used by interdisciplinary authors, editors, and peer reviewers to verify that each component of a search is completely reported and therefore reproducible.

20 July 2021 in Journal of the Medical Library Association
Verified
Journal Article
Open access
PDF file
MRMelissa Rethlefsen
Melissa Rethlefsen
SKShona Kirtley
Shona Kirtley
SWSiw Waffenschmidt
Siw Waffenschmidt
AAAna Patricia Ayala
Ana Patricia Ayala
DMDavid Moher
David Moher
JKJonathan B. Koffel
Jonathan B. Koffel
Background: Literature searches underlie the foundations of systematic reviews and related review types. Yet, the literature searching component of systematic reviews and related review types is often poorly reported. Guidance for literature search reporting has been diverse and, in many cases, does not offer enough detail to authors who need more specific information about reporting search methods and information sources in a clear, reproducible way. This document presents the PRISMA-S (Preferred Reporting Items for Systematic reviews and Meta-Analyses literature search extension) checklist, and explanation and elaboration.Methods: The checklist was developed using a three-stage Delphi survey process, followed by a consensus conference and public review process.Results: The final checklist includes sixteen reporting items, each of which is detailed with exemplar reporting and rationale.Conclusions:The intent of PRISMA-S is to complement the PRISMA Statement and its extensions by providing a checklist that could be used by interdisciplinary authors, editors, and peer reviewers to verify that each component of a search is completely reported and, therefore, reproducible.

1 February 2019 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
JHJoris Hemelaar
Joris Hemelaar
RERamyiadarsini Elangovan
Ramyiadarsini Elangovan
JYJason Yun
Jason Yun
LDLeslie Dickson-Tetteh
Leslie Dickson-Tetteh
IFIsabella Fleminger
Isabella Fleminger
RZRong Zhang
Rong Zhang

13 June 2019 in Human Reproduction Update
Verified
Journal Article
Open access
PDF file
NSNina Shigesi
Nina Shigesi
MKMarina Kvaskoff
Marina Kvaskoff
SKShona Kirtley
Shona Kirtley
QFQian Feng
Qian Feng
HFHai Fang
Hai Fang
CBChristian Becker
Christian Becker
BACKGROUND: Endometriosis is a chronic gynaecological disorder that affects 2–10% of women of reproductive age. The aetiology of endometriosis is largely under-explored, yet abnormalities in the immune system have been suggested to explain the origin of ectopic endometrial tissues, and an association between endometriosis and autoimmune diseases has been proposed. Evaluation of current evidence investigating the association between endometriosis and autoimmune diseases from population-based studies will facilitate our understanding of the causes and consequences of endometriosis and provide a reference for better healthcare practices population-wide.OBJECTIVE AND RATIONALE: The aim of this study was to systematically review the literature on population-based studies investigating an association between endometriosis and autoimmune diseases and to conduct a meta-analysis of combinable results to investigate the extent and robustness of evidence.SEARCH METHODS: Four electronic databases were searched (MEDLINE, Embase, Web of Science, and CINAHL) from each database inception date until 7 April 2018. Search terms included a combination of database-specific controlled vocabulary terms and free-text terms relating to ‘endometriosis’ and ‘autoimmune diseases’. Study inclusion criteria focused on peer-reviewed published articles that reported an association between endometriosis and autoimmune diseases, excluding case reports/series, review papers, meta-analyses, organizational guidelines, editorial letters, expert opinions, and conference abstracts. Quality assessment of included studies was performed based on GRADE criteria. Key information of eligible studies was abstracted into a standard form. Meta-analysis was performed for autoimmune diseases with combinable study results from at least three studies investigating an association with endometriosis. For cross-sectional studies and case–control studies, raw data from each study were documented to calculate a Mantel–Haenszel odds ratio with 95% CIs. For cohort studies, an inverse variance probability weighted model was used to pool study results to calculate a rate ratio (a hazard ratio or a standardized incidence rate) with 95% CIs.OUTCOMES: A total of 26 published population-based cross-sectional, case–control, and cohort studies that investigated the association between endometriosis and autoimmune diseases met all eligible criteria and were included in the review. The studies quantified an association between endometriosis and several autoimmune diseases, including systemic lupus erythematosus (SLE), Sjögren’s syndrome (SS), rheumatoid arthritis (RA), autoimmune thyroid disorder, coeliac disease (CLD), multiple sclerosis (MS), inflammatory bowel disease (IBD), and Addison’s disease. However, the quality of the evidence was generally poor due to the high risk of bias in the majority of the chosen study designs and statistical analyses. Only 5 of the 26 studies could provide high-quality evidence, and among these, 4 supported a statistically significant association between endometriosis and at least 1 autoimmune disease: SLE, SS, RA, CLD, MS, or IBD.WIDER IMPLICATIONS: The observed associations between endometriosis and autoimmune diseases suggest that clinicians need to be aware of the potential coexistence of endometriosis and autoimmune diseases when either is diagnosed. Scientists interested in research studies on endometriosis or autoimmune diseases should consider the likelihood of comorbidity when studying these two types of health conditions. Well-designed large prospective cohort studies with confounding control and mediation quantification, as well as genetic and biological studies, are needed to generate further insights into whether endometriosis is a risk factor for, or a consequence of, autoimmune diseases, and whether these two types of disorders share pathophysiological mechanisms even if they arise independently. Such insights may offer opportunities for the development of novel non-hormonal medications such as immuno-modulators or repurposing of existing immunomodulatory therapies for endometriosis.

20 May 2020 in BMJ
Verified
Journal Article
Open access
PDF file
SGStephen Gerry
Stephen Gerry
TBTimothy Bonnici
Timothy Bonnici
JBJacqueline Birks
Jacqueline Birks
SKShona Kirtley
Shona Kirtley
PVPradeep S Virdee
Pradeep S Virdee
GCGary S Collins
Gary S Collins
Objective To provide an overview and critical appraisal of early warning scores for adult hospital patients. Design Systematic review. Data sources Medline, CINAHL, PsycInfo, and Embase until June 2019. Eligibility criteria for study selection Studies describing the development or external validation of an early warning score for adult hospital inpatients. Results 13 171 references were screened and 95 articles were included in the review. 11 studies were development only, 23 were development and external validation, and 61 were external validation only. Most early warning scores were developed for use in the United States (n=13/34, 38%) and the United Kingdom (n=10/34, 29%). Death was the most frequent prediction outcome for development studies (n=10/23, 44%) and validation studies (n=66/84, 79%), with different time horizons (the most frequent was 24 hours). The most common predictors were respiratory rate (n=30/34, 88%), heart rate (n=28/34, 83%), oxygen saturation, temperature, and systolic blood pressure (all n=24/34, 71%). Age (n=13/34, 38%) and sex (n=3/34, 9%) were less frequently included. Key details of the analysis populations were often not reported in development studies (n=12/29, 41%) or validation studies (n=33/84, 39%). Small sample sizes and insufficient numbers of event patients were common in model development and external validation studies. Missing data were often discarded, with just one study using multiple imputation. Only nine of the early warning scores that were developed were presented in sufficient detail to allow individualised risk prediction. Internal validation was carried out in 19 studies, but recommended approaches such as bootstrapping or cross validation were rarely used (n=4/19, 22%). Model performance was frequently assessed using discrimination (development n=18/22, 82%; validation n=69/84, 82%), while calibration was seldom assessed (validation n=13/84, 15%). All included studies were rated at high risk of bias. Conclusions Early warning scores are widely used prediction models that are often mandated in daily clinical practice to identify early clinical deterioration in hospital patients. However, many early warning scores in clinical use were found to have methodological weaknesses. Early warning scores might not perform as well as expected and therefore they could have a detrimental effect on patient care. Future work should focus on following recommended approaches for developing and evaluating early warning scores, and investigating the impact and safety of using these scores in clinical practice. Systematic review registration PROSPERO CRD42017053324.

12 May 2010 in Human Reproduction Update
Verified
Journal Article
Open access
PDF file
KMK. E. May
K. E. May
SCS. A. Conduit-Hulbert
S. A. Conduit-Hulbert
JVJ. Villar
J. Villar
SKS. Kirtley
S. Kirtley
SKS. H. Kennedy
S. H. Kennedy
CBChristian Becker
Christian Becker
Endometriosis is estimated to affect 1 in 10 women during the reproductive years. There is often delay in making the diagnosis, mainly due to the non-specific nature of the associated symptoms and the need to verify the disease surgically. A biomarker that is simple to measure could help clinicians to diagnose (or at least exclude) endometriosis; it might also allow the effects of treatment to be monitored. If effective, such a marker or panel of markers could prevent unnecessary diagnostic procedures and/or recognize treatment failure at an early stage. We used QUADAS (Quality Assessment of Diagnostic Accuracy Studies) criteria to perform a systematic review of the literature over the last 25 years to assess critically the clinical value of all proposed biomarkers for endometriosis in serum, plasma and urine. We identified over 100 putative biomarkers in publications that met the selection criteria. We were unable to identify a single biomarker or panel of biomarkers that have unequivocally been shown to be clinically useful. Peripheral biomarkers show promise as diagnostic aids, but further research is necessary before they can be recommended in routine clinical care. Panels of markers may allow increased sensitivity and specificity of any diagnostic test.